Next Frontier in HER2+/HR+ Breast Cancer: Leveraging Cell Cycle Control with CDK4/6 Inhibitors

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• HER2-positive/hormone-receptor-positive breast cancer (10% of cases) presents unique resistance challenges to anti-HER2 therapies.
• Crosstalk between HER2 and estrogen receptor pathways converges on cell cycle regulation (cyclin D1-CDK4/6-Rb axis).
• This convergence provides a rationale for combining CDK4/6 inhibitors with HER2-targeted therapy.

Purpose of the Study:

• To map preclinical and clinical evidence on CDK4/6 inhibitor combinations with HER2-targeted therapy in HER2+/HR+ breast cancer.
• To synthesize data on efficacy, safety, and challenges in this therapeutic combination.

Main Methods:

• Scoping review methodology adhering to PRISMA-ScR guidelines.
• Searches conducted across PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov.
• Data charted and synthesized descriptively from preclinical models and clinical trials.

Main Results:

• Preclinical studies show synergistic activity of CDK4/6 inhibitors with trastuzumab, pertuzumab, and other HER2 agents.
• Phase II/III trials (MonarcHER, PATRICIA II, PATINA) demonstrate encouraging efficacy, including a 15.2-month PFS benefit in the metastatic setting.
• Neoadjuvant trials (NA-PHER2, MUKDEN-01) show significant Ki67 suppression and pathologic responses, supporting chemotherapy de-escalation.

Conclusions:

• CDK4/6 inhibitors combined with HER2-targeted therapy represent a promising strategy for HER2+/HR+ breast cancer.
• Challenges include biomarker identification, treatment sequencing, and integrating novel agents like trastuzumab deruxtecan.
• Precision medicine approaches leveraging cell cycle control are crucial for improving outcomes.